MIM
SYRE icon

MetLife Investment Management’s Spyre Therapeutics SYRE Stock Holding History

MetLife Investment Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.85M Buy
43,316
+4,909
+13% +$358K 0.02% 787
2026
Q1 		$1.94M Buy
38,407
+396
+1% +$14.9K 0.01% 1075
2025
Q4 		$1.25M Buy
38,011
+8,093
+27% +$211K 0.01% 1305
2025
Q3 		$501K Hold
29,918
– – ﹤0.01% 1803
2025
Q2 		$448K Buy
29,918
+6,185
+26% +$91.5K ﹤0.01% 1732
2025
Q1 		$383K Buy
23,733
+2,351
+11% +$48.9K ﹤0.01% 1859
2024
Q4 		$498K Buy
21,382
+1,250
+6% +$36.7K ﹤0.01% 1799
2024
Q3 		$592K Buy
20,132
+11,344
+129% +$316K ﹤0.01% 1686
2024
Q2 		$207K Buy
+8,788
New +$296K ﹤0.01% 2224
2021
Q4 		– Sell
-614
Closed -$122K – 2551
2021
Q3 		$122K Buy
+614
New +$107K ﹤0.01% 2351
2021
Q2 		– Sell
-811
Closed -$161K – 2484
2021
Q1 		$161K Buy
811
+491
+153% +$94.2K ﹤0.01% 2162
2020
Q4 		$62.9K Sell
320
-485
-60% -$101K ﹤0.01% 2247
2020
Q3 		$143K Hold
805
– – ﹤0.01% 2049
2020
Q2 		$186K Buy
+805
New +$153K ﹤0.01% 1951
2019
Q4 		– Sell
-565
Closed -$109K – 2325
2019
Q3 		$109K Buy
+565
New +$110K ﹤0.01% 2287

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

MetLife Investment Management's SYRE Position: Q2 2026 in Review

MetLife Investment Management increased its Spyre Therapeutics (SYRE) stake by 13% in Q2 2026, buying an estimated $358K and bringing the position to 43,316 shares worth $3.85M. The position accounts for 0.02% of the portfolio, ranked #787.

MetLife Investment Management first reported a position in SYRE in Q3 2019 and has held it in 15 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • MetLife Investment Management held 43,316 shares of Spyre Therapeutics worth $3.85M as of Q2 2026.
  • MetLife Investment Management bought 4,909 Spyre Therapeutics shares in Q2 2026, an estimated $358K.
  • Spyre Therapeutics made up 0.02% of MetLife Investment Management's portfolio in Q2 2026, its #787 holding.
  • MetLife Investment Management first reported a position in Spyre Therapeutics in Q3 2019 and has held it in 15 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.